Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
…
continue reading
Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.
…
continue reading
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
…
continue reading
Medical Industry Feature highlights topics brought to you by makers of products and services in the medical industry.
…
continue reading
Welcome to the Clinical Care Solutions Oncology podcast channel. Our podcast shows give you quick access to important content when you need it - at home, at your desk, or on the go.
…
continue reading
Neuropscyhotherapist and Mental Health Correspondent, Bella J. Rockman, M.A., LPC provides contemporary and cutting edge commentary on current events and Mental Health & Wellness topics. The Jrocktherapy Podcast is designed to empower you with brain based Behavioral Health therapeutic tools. Subscribe for updates at www.jrocktherapyinstitute.com IG: @jrocktherapy Support this podcast: https://podcasters.spotify.com/pod/show/bella-rockman/support
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Scaling Allo with Allogene Therapeutics' Dr. Zachary Roberts
25:13
25:13
Play later
Play later
Lists
Like
Liked
25:13
We love to hear from our listeners. Send us a message. Allogene Therapeutics' EVP of R&D and CMO, Dr. Zachary Roberts, penned an original article for Cell & Gene titled, The Path Forward for CLL is Allogeneic. In his article, Dr. Roberts explains that chronic lymphocytic leukemia (CLL) is the most common leukemia in the U.S. And that while CLL rema…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ROS1-Alterations and Molecular Testing in Advanced NSCLC
16:28
16:28
Play later
Play later
Lists
Like
Liked
16:28
In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its implications for molecular testing and treatment selection including: ROS1-gene fusions in advanced lung cancer ROS1 testing recommendations with DNA …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer
1:01:23
1:01:23
Play later
Play later
Lists
Like
Liked
1:01:23
Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.By Neil Love, MD
…
continue reading
Host: Jennifer Caudle, DO Guest: Samuel R. Wilson, MD Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CGT Regulatory Update and Outlook with Dark Horse Consulting's Kimberly Benton, Ph.D.
27:58
27:58
Play later
Play later
Lists
Like
Liked
27:58
We love to hear from our listeners. Send us a message. Applications (BLAs) of recent approvals and complete responses for novel products or rare diseases as well as BLAs currently under review. Benton shares information about FDA Draft Gudiances, including Platform Technology Designation Program for Drug Development: Guidance for Industry. She also…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer
1:01:43
1:01:43
Play later
Play later
Lists
Like
Liked
1:01:43
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jessie Hsieh, MD Guest: David Isaacson, MD About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this ga…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
1:00:53
1:00:53
Play later
Play later
Lists
Like
Liked
1:00:53
Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers
49:32
49:32
Play later
Play later
Lists
Like
Liked
49:32
In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including: RUBY Part 1 Subgroup …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Identifying Drug Development Opportunities for DMD with CureDuchenne
29:55
29:55
Play later
Play later
Lists
Like
Liked
29:55
We love to hear from our listeners. Send us a message. Debra Miller, CEO and Founder and Dr. Michael Kelly, Chief Scientific Officer at CureDuchenne talk to Host Erin Harris about the FDA approval for the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics as well as how CureDuchenne works with various biotechs developing gene …
…
continue reading
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Leigh Anne Cantrell, MD, MSPH The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation
47:34
47:34
Play later
Play later
Lists
Like
Liked
47:34
Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
34:45
34:45
Play later
Play later
Lists
Like
Liked
34:45
In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer. Presenters: Virginia Kaklamani, MD, DSc Prof…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Current Clinical Practice and NCCN Guidelines for CLL/SLL
31:33
31:33
Play later
Play later
Lists
Like
Liked
31:33
In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including: Prognostic variables when deciding between regimens Role of MRD in CLL Results from the phase II CAPTIVATE trial Choosing among th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Tackling "The Delivery Problem" of Gene Editing-Based Medicines with Mammoth Biosciences' Lucas Harrington
21:01
21:01
Play later
Play later
Lists
Like
Liked
21:01
We love to hear from our listeners. Send us a message. Lucas Harrington, Co-Founder and Chief Scientific Officer of Mammoth Biosciences, joins Erin Harris to shed light on the biotech's proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. They discuss…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs
28:35
28:35
Play later
Play later
Lists
Like
Liked
28:35
In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including: Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the M…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways
24:23
24:23
Play later
Play later
Lists
Like
Liked
24:23
In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including: Rationale for targeting CELMoDs in NHL Mechanism of action of CELMoDs Key studies and available efficacy and safety data with investigational CELMoDs in NHL Key ongoing clinical trials of CELMoDs in NHL Strategies to…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer
24:30
24:30
Play later
Play later
Lists
Like
Liked
24:30
In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemacicli…
…
continue reading
Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with p…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for AML
25:21
25:21
Play later
Play later
Lists
Like
Liked
25:21
In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractor…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Congress to Clinic: Expert Takeaways on Emerging Data for MDS
19:19
19:19
Play later
Play later
Lists
Like
Liked
19:19
In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including: COMMANDS trial of luspatercept in transfusion-dependent, erythropoietin stimulating agent–naive, very low…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
TILs for the Treatment of Solid Tumors with KSQ Therapeutics' Micah Benson, Ph.D.
35:30
35:30
Play later
Play later
Lists
Like
Liked
35:30
We love to hear from our listeners. Send us a message. KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the S…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Synthetic Biology and Programmable mRNA with Strand Therapeutics' Jake Becraft
27:52
27:52
Play later
Play later
Lists
Like
Liked
27:52
We love to hear from our listeners. Send us a message. Strand Therapeutics' CEO and Co-Founder Jake Becraft joins Erin Harris to discuss genetic regulation and how the company's programmable mRNA constructs combine genes for self-replication derived from RNA viruses with genetically programmed logic circuits that control the location, timing, and i…
…
continue reading
Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc Guest: Dru Riddle, PhD, DNP, CRNA When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
1:00:48
1:00:48
Play later
Play later
Lists
Like
Liked
1:00:48
Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Developing an mRNA Therapy for DMD with Elixirgen Therapeutics' Aki Ko
14:52
14:52
Play later
Play later
Lists
Like
Liked
14:52
We love to hear from our listeners. Send us a message. Elixirgen Therapeutics' Aki Ko joins Erin Harris to detail the company's Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.…
…
continue reading
Guest: Lori J. Wirth, MD Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston. References: Gormley M, et al. Br …
…
continue reading
Host: Jennifer Caudle, DO Guest: Joyce O'Shaughnessy, MD The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocr…
…
continue reading
Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Current State of the Global Regulatory Landscape with ISCT's Dr. Bambi Grilley
25:21
25:21
Play later
Play later
Lists
Like
Liked
25:21
We love to hear from our listeners. Send us a message. Dr. Bambi Grilley is Professor of Pediatrics and the Director of Clinical Research and Early Product Development for the Center of Cell and Gene Therapy (CAGT) at Baylor College of Medicine AND she is Chief Regulatory Officer at ISCT. Dr. Grilley talks to us about her role as CRO at ISCT and th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Dr. Bruce Levine on ISCT and the Future of CAR-T
31:49
31:49
Play later
Play later
Lists
Like
Liked
31:49
We love to hear from our listeners. Send us a message. In anticipation of ISCT 2024 in Vancouver, Canada, Dr. Bruce Levine is back on Cell & Gene: The Podcast to share information about the event as well as his expertise on the future of CAR-T therapy for solid tumors, autoimmune disease, and more. He talks about his time and learnings as President…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: William F.C. Rigby, MD Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition that can be difficult to diagnose and treat. For instance, PMR is a diagnosis of exclusion, and it can mimic a wide variety of other conditions. And once a patient is accurately diagnosed, the standard-of-care t…
…
continue reading
Guest: Adam Narloch Guest: Michelle Hermiston, MD, PhD Adam Narloch speaks with Dr Michelle Hermiston to discuss the history of hemophagocytic lymphohistiocytosis (HLH) and advances in understanding this rare disease. Dr Hermiston is a pediatric hematologist-oncologist, a bone marrow transplant specialist, and the Director of the Pediatric Immunoth…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer
25:55
25:55
Play later
Play later
Lists
Like
Liked
25:55
In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast canc…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CGTs for HIV Suppression with Addimmune's Dr. Marcus Conant
18:51
18:51
Play later
Play later
Lists
Like
Liked
18:51
We love to hear from our listeners. Send us a message. Dr. Marcus Conant is CMO at Addimmune, a biotech startup developing a cell therapy for HIV that spun out of cell and gene therapy biotech American Gene Technologies (AGT). He spent his career on the front lines of HIV treatment and research and remains an advocate for the HIV patient. He formed…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
47:23
47:23
Play later
Play later
Lists
Like
Liked
47:23
In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your clinical practice to optimize treatment and outcomes. The greater discussion addresses: Optimal selection of therapy for treatment-naive CLL, includin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Inside BlueRock Therapeutics' Parkinson's Disease Trial with Dr. Ahmed Enayetallah
29:39
29:39
Play later
Play later
Lists
Like
Liked
29:39
We love to hear from our listeners. Send us a message. BlueRock Therapeutics' SVP Head of Development, Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripote…
…
continue reading
Host: Richard Lafayette, MD, FACP Expert Nephrologist Richard Lafayette, MD, FACP, gives an overview of top abstracts from Kidney Week 2023 and updates on emerging therapies for IgAN.
…
continue reading
Guest: Dena Goffman, MD Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a n…
…
continue reading
Guest: Michael Kaplitt, MD, PhD For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The r…
…
continue reading
Guest: Pierre Elias, MD In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose pat…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Arnaud Bourdin, MD, PhD Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang
23:08
23:08
Play later
Play later
Lists
Like
Liked
23:08
We love to hear from our listeners. Send us a message. In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead engineered hematopoietic cell (eHSC) product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast Host, Erin Harris, about how Vor has treated 8 patients demonstrating clinical proo…
…
continue reading
Guest: Christopher Petit, MD Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ …
…
continue reading
Guest: Conor Liston, MD, PhD For patients diagnosed with depression for the first time the recommended course of treatment is the same; however, there’s a large patient population for whom these treatments won’t work. So it became increasingly important for Dr. Liston to map the brains of people suffering from major depression to see how it was imp…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates
32:24
32:24
Play later
Play later
Lists
Like
Liked
32:24
Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.By Neil Love, MD
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
48:15
48:15
Play later
Play later
Lists
Like
Liked
48:15
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including: Rationale for targeting PARP in prostate cancer with ARI combinations Study design nuances and findings from key randomiz…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Reducing Toxicities in Allogeneic Cell Therapies with Orca Bio's Dr. Scott McClellan
19:37
19:37
Play later
Play later
Lists
Like
Liked
19:37
We love to hear from our listeners. Send us a message. Orca Bio's CMO, Dr. Scott McClellan, joins Erin Harris on this episode of Cell & Gene: The Podcast to discuss how and why toxicities continue to stymie allogeneic cell therapies. They cover Orca Bio's plan to potentially lowering the risk of GvHD as well as Orca-T, the investigational high-prec…
…
continue reading
Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer
1:02:57
1:02:57
Play later
Play later
Lists
Like
Liked
1:02:57
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.By Neil Love, MD
…
continue reading